Allopregnanolone
Mild Alzheimer's Disease
Phase 2bActive
Key Facts
About NeuTherapeutics
NeuTherapeutics is a clinical-stage biotechnology company with a dual focus on neurodegenerative diseases and women's brain health. Its lead asset, Allopregnanolone, is a regenerative therapy for Alzheimer's Disease currently in a Phase 2b trial (REGEN-BRAIN©), with the ambitious goal of halting or reversing disease progression. The company also markets PhytoSERM, a plant-based dietary supplement for menopausal symptoms, which provides an early revenue stream and aligns with its broader brain health mission. Operating as a private entity, NeuTherapeutics emphasizes precision medicine, rigorous clinical evidence, and patentable drug-delivery strategies to achieve its vision.
View full company profileTherapeutic Areas
Other Mild Alzheimer's Disease Drugs
| Drug | Company | Phase |
|---|---|---|
| Foralumab (intranasal) | Tiziana Life Sciences | Phase 2 |
| Laromestrocel (Lomecel-B™) | Longeveron | Phase 2a |